U.S. markets open in 20 minutes
  • S&P Futures

    3,846.00
    +18.00 (+0.47%)
     
  • Dow Futures

    31,360.00
    -11.00 (-0.04%)
     
  • Nasdaq Futures

    12,966.50
    +134.75 (+1.05%)
     
  • Russell 2000 Futures

    2,203.00
    +3.00 (+0.14%)
     
  • Crude Oil

    62.50
    -1.03 (-1.62%)
     
  • Gold

    1,760.50
    -14.90 (-0.84%)
     
  • Silver

    26.91
    -0.78 (-2.82%)
     
  • EUR/USD

    1.2129
    -0.0058 (-0.47%)
     
  • 10-Yr Bond

    1.4720
    -0.0460 (-3.03%)
     
  • Vix

    27.99
    +6.65 (+31.16%)
     
  • GBP/USD

    1.3973
    -0.0040 (-0.28%)
     
  • USD/JPY

    106.3440
    +0.1140 (+0.11%)
     
  • BTC-USD

    46,293.48
    -5,402.80 (-10.45%)
     
  • CMC Crypto 200

    926.05
    -7.09 (-0.76%)
     
  • FTSE 100

    6,538.50
    -113.46 (-1.71%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate

  • Oops!
    Something went wrong.
    Please try again later.
Priya Nigam
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The market’s skepticism around Aptinyx Inc’s (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler.

The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10.

The Aptinyx Thesis: Apart from the PTSD candidate, another two modulators show “meaningful potential,” which could lend upside to the stock over the intermediate- to longer-term, Raymond said.

“We understand the skepticism around PTSD but objectively, NYX-783 is the most promising agent in this condition in decades... And with management guiding to initiation of a pivotal trial next year, we think any sign of tacit FDA endorsement of these data is likely to be stock-moving,” he wrote in a note.

“Alongside NYX-783, another high-potential NMDAR modulator is NYX-2925, which should restart P2 enrollment in painful diabetic peripheral neuropathy this quarter, with POC data by 2022,” the analyst added.

Combining these compounds, the worldwide end-user revenue estimates are $159 million, $372 million, $605 million, $867 million, and $1.1 billion for 2026 through 2030, respectively, Raymond said.

APTX Price Action: Shares of Aptinyx were down 2% to $2.92 at the time of publication Tuesday.

Latest Ratings for APTX

Oct 2020

Piper Sandler

Initiates Coverage On

Overweight

May 2020

William Blair

Initiates Coverage On

Outperform

Apr 2020

HC Wainwright & Co.

Initiates Coverage On

Buy

View More Analyst Ratings for APTX
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.